Atea Pharmaceuticals (AVIR)

• Market cap: $359M
• 1 day: 0%
• 5 days: 4.92%
• 1 month: -1.1%
• 3 months: -15.95%
• 6 months: 23.76%
• Year to date: 28.74%
• 1 year: 32.54%
• 5 years: -80.87%
• 10 years: -85.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Employees: 55